{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:23:03Z","timestamp":1764937383926,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The purpose of this study was to determine the safety and effectiveness of simultaneous vitreous injection of dexamethasone implant and ranibizumab on macular edema secondary to central retinal vein occlusion (CRVO). We conducted a 6-month retrospective self-control study. Twenty-five patients diagnosed with macular edema secondary to CRVO were enrolled in this study. The patients received intravitreal injection of dexamethasone implant and ranibizumab. The changes in best corrected visual acuity (BCVA), central retinal thickness (CRT) and interocular pressure (IOP) before and at 2w, 1, 2, 3, 4, 5, 6\u00a0m after injection were recorded and compared. The adverse reactions in eyes and whole body were observed. The BCVA of all patients at 2\u00a0w (61.8 \u00b1 5.42), 1\u00a0m (68.68 \u00b1 5.23), 2\u00a0m (70.8 \u00b1 5.8), 3\u00a0m (68.44 \u00b1 5.61), 4\u00a0m (65.76 \u00b1 5.76), 5\u00a0m (67.08 \u00b1 5.57), and 6\u00a0m (70.12 \u00b1 5.46) after surgery were significantly higher than that before surgery (52.2 \u00b1 5.06,<jats:italic>p<\/jats:italic> &amp;lt; 0.01), and CRT of all patients at 2w (393.36 \u00b1 52.66\u00a0um), 1\u00a0m (334.52 \u00b1 32.95\u00a0um), 2\u00a0m (298.800 \u00b1 29.97\u00a0um), 3\u00a0m (309.080 \u00b1 28.78\u00a0um), 4\u00a0m (345.48 \u00b1 39.81\u00a0um), 5\u00a0m (349.080 \u00b1 29.88\u00a0um), and 6\u00a0m (309.76 \u00b1 30.41\u00a0um) after surgery were significantly reduced than that before surgery (583.76 \u00b1 121.09\u00a0um, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). Macular edema recurred in an average of 4.44 \u00b1 0.51\u00a0months after treatment, and those patients received combined treatment again. During follow-up, the most common adverse reactions were subconjunctival hemorrhage and increased intraocular pressure, with the incidence of 22% (11\/50) and 18% (9\/50) respectively. In all cases, the increased intraocular pressure could be controlled by a single intraocular pressure reducing drug. No patient needed to receive anti-glaucoma surgery. The overall incidence of lens opacity was 4% (2\/50). After the first injection, no case showed lens opacity. After re-injection, 2 patients (2 eyes) (8%) developed lens opacity. None of the patients showed serious ocular adverse reactions or systemic complications such as vitreous hemorrhage, retinal detachment, endophthalmitis, uveitis or ocular toxicity. The simultaneous vitreous injection of dexamethasone implant and ranibizumab can significantly improve the visual acuity and anatomical prognosis in macular edema secondary to central retinal vein occlusion (CRVO-ME) patients, exhibiting good safety and effectiveness.<\/jats:p>","DOI":"10.3389\/fphar.2022.842805","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:19:01Z","timestamp":1646119141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion"],"prefix":"10.3389","volume":"13","author":[{"given":"Xing","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjuan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeqiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.phrs.2016.07.042","article-title":"Nanosystems Based on siRNA Silencing HuR Expression Counteract Diabetic Retinopathy in Rat","volume":"111","author":"Amadio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1055\/s-0042-123834","article-title":"Retinal Vein Occlusion - Which Treatment when?","volume":"234","author":"Bajor","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained Benefits from Ranibizumab for Macular Edema Following branch Retinal Vein Occlusion: 12-month Outcomes of a Phase III Study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal Aflibercept Injection for Macular Edema Secondary to central Retinal Vein Occlusion: 1-year Results from the Phase 3 COPERNICUS Study","volume":"155","author":"Brown","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jphs.2018.11.001","article-title":"Long-term Efficacy and Safety Profile of Multiple Injections of Intravitreal Dexamethasone Implant to Manage Diabetic Macular Edema: A Systematic Review of Real-World Studies","volume":"138","author":"Bucolo","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular Endothelial Growth Factor Promotes Progressive Retinal Nonperfusion in Patients with Retinal Vein Occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/ejo.5000376","article-title":"Retreatment with Ozurdex for Macular Edema Secondary to Retinal Vein Occlusion","volume":"24","author":"Coscas","year":"2014","journal-title":"Eur. J. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/archopht.124.5.726","article-title":"Ten-year Incidence of Retinal Vein Occlusion in an Older Population: the Blue Mountains Eye Study","volume":"124","author":"Cugati","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.exer.2004.09.013","article-title":"Corticosteroids Inhibit VEGF-Induced Vascular Leakage in a Rabbit Model of Blood-Retinal and Blood-Aqueous Barrier Breakdown","volume":"80","author":"Edelman","year":"2005","journal-title":"Exp. Eye Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/02713680500263598","article-title":"Glucocorticoid Regulation of Endothelial Cell Tight junction Gene Expression: Novel Treatments for Diabetic Retinopathy","volume":"30","author":"Felinski","year":"2005","journal-title":"Curr. Eye Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0014-2999(00)00915-8","article-title":"In Vitro effects of Dexamethasone on Hypoxia-Induced Hyperpermeability and Expression of Vascular Endothelial Growth Factor","volume":"411","author":"Fischer","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"B13","first-page":"69","article-title":"Mechanism of Steroid Action in Ocular Inflammation: Inhibition of Prostaglandin Production","volume":"16","author":"Floman","year":"1977","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/15569527.2019.1614020","article-title":"Efficacy and Safety of Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion Resistant to Anti-VEGF Therapy: a 12-month Prospective Study","volume":"38","author":"Georgalas","year":"2019","journal-title":"Cutan. Ocul. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to branch or central Retinal Vein Occlusion Twelve-Month Study Results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural History of Visual Outcome in central Retinal Vein Occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Long-Term Follow-Up in the HORIZON Trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OPTH.S241044","article-title":"Combination Therapy for Macular Oedema in Retinal Vein Occlusions: 3-Year Results from a Real-World Clinical Practice","volume":"14","author":"Horner","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1089\/jop.2018.0012","article-title":"Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy","volume":"34","author":"Houben","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.4103\/ijo.IJO_382_19","article-title":"Comparison between Ozurdex and Intravitreal Anti-vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusion-Related Macular Edema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"67","author":"Hu","year":"2019","journal-title":"Indian J. Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjophthalmol-2014-305661","article-title":"Sequential Therapy with Ranibizumab and Dexamethasone Intravitreal Implant Is Better Than Dexamethasone Monotherapy for Macular Oedema Due to Retinal Vein Occlusion","volume":"99","author":"Iu","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for Macular Oedema Secondary to Retinal Vein Occlusion: a Prospective Study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of Disease of Retinal Vein Occlusion: Review of the Literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye (Lond)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","article-title":"Safety and Efficacy of Dexamethasone Intravitreal Implant for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in Chinese Patients: Randomized, Sham-Controlled, Multicenter Study","volume":"256","author":"Li","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"SAFETY of INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX Study. Incidence and Risk Factors of Ocular Hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"B27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10792-016-0226-3","article-title":"Outcome of Intravitreal Dexamethasone Implant for the Treatment of Ranibizumab-Resistant Macular Edema Secondary to Retinal Vein Occlusion","volume":"37","author":"Manousaridis","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e032128","DOI":"10.1136\/bmjopen-2019-032128","article-title":"Comparison of Intravitreal Dexamethasone Implant and Anti-VEGF Drugs in the Treatment of Retinal Vein Occlusion-Induced Oedema: a Meta-Analysis and Systematic Review","volume":"10","author":"Ming","year":"2020","journal-title":"BMJ Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00417-004-1087-4","article-title":"Intravitreal Levels of Vascular Endothelial Growth Factor and Interleukin-6 Are Correlated with Macular Edema in branch Retinal Vein Occlusion","volume":"244","author":"Noma","year":"2006","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e78538","DOI":"10.1371\/journal.pone.0078538","article-title":"Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to branch and central Retinal Vein Occlusion: a Systematic Review","volume":"8","author":"Pielen","year":"2013","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"P182","DOI":"10.1016\/j.ophtha.2015.10.045","article-title":"Retinal Vein Occlusions Preferred Practice Pattern(\u00ae) Guidelines","volume":"123","author":"Pulido","year":"2016","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e022700","DOI":"10.1136\/bmjopen-2018-022700","article-title":"Comparison of the Efficacy and Safety of Drug Therapies for Macular Edema Secondary to central Retinal Vein Occlusion","volume":"8","author":"Qian","year":"2018","journal-title":"BMJ Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1097\/IAE.0000000000000524","article-title":"Observed Complications from Dexamethasone Intravitreal Implant for the Treatment of Macular Edema in Retinal Vein Occlusion over 3 Treatment Rounds","volume":"35","author":"Reid","year":"2015","journal-title":"Retina"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/aos.13152","article-title":"Effect of Intravitreal Dexamethasone Implant on Intra-ocular Cytokines and Chemokines in Eyes with Retinal Vein Occlusion","volume":"95","author":"Rezar-Dreindl","year":"2017","journal-title":"Acta Ophthalmol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1586\/ecp.12.55","article-title":"Pharmacologic and Clinical Profile of Dexamethasone Intravitreal Implant","volume":"5","author":"Robinson","year":"2012","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","article-title":"Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA)","volume":"242","author":"Schmidt-Erfurth","year":"2019","journal-title":"Ophthalmologica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0b013e318242b838","article-title":"Effect of Combination Therapy with Bevacizumab and Dexamethasone Intravitreal Implant in Patients with Retinal Vein Occlusion","volume":"32","author":"Singer","year":"2012","journal-title":"Retina"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e8158","DOI":"10.1371\/journal.pone.0008158","article-title":"Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal Diseases","volume":"4","author":"Yoshimura","year":"2009","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1167\/iovs.11-7675","article-title":"Differential Regulations of AQP4 and Kir4.1 by Triamcinolone Acetonide and Dexamethasone in the Healthy and Inflamed Retina","volume":"52","author":"Zhao","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.842805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T07:19:03Z","timestamp":1646119143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.842805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":40,"alternative-id":["10.3389\/fphar.2022.842805"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.842805","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"842805"}}